authors request that the following correction be noted. On page 7927 in the Abstract, diazepam binding inhibitor [33] [34] [35] [36] [37][38][39][40][41][42][43][44][45][46][47][48][49][50] is mentioned incorrectly and should read: ''Similarly, diazepam binding inhibitor 33-52 also stimulated CCK release and pancreatic secretion in a dosedependent manner although it was 100 times less potent than the whole peptide.'' Also, due to a printer's error, the corresponding author's address should read D-24105 Kiel.
creatic secretion in a dose-dependent manner although it was 100 times less potent than the whole peptide. Using a perfusion system containing isolated mucosal cells from the proximal intestine of rats, porcine diazepam binding inhibitor (10-9-10-12 M) dose dependently stimulated CCK secretion. In separate studies, it was demonstrated that luminal secretion of the diazepam binding inhibitor immunoreactivity (7.5 x 10-1" M) could be detected in rat's intestinal washing following the diversion of bile-pancreatic juice. The secretion of this peptide was inhibited by atropine. In conclusion, we have isolated and characterized a CCK-releasing peptide that has a sequence identical to the porcine diazepam binding inhibitor from pig intestinal mucosa and that stimulates CCK release when administered intraduodenally in rat. This peptide may mediate feedback regulation of pancreatic enzyme secretion.
In animals, it has been shown that proteases such as trypsin in the duodenum exert a negative feedback control for pancreatic enzyme secretion. Exocrine pancreatic secretion is stimulated by feeding raw soy flour containing a potent protease inhibitor (1) . In addition, diversion of bile-pancreatic juice also stimulates pancreatic secretion (2) . This phenomenon has also been observed in pigs (3) , chickens (4) , and humans (5) . In rats, cholecystokinin (CCK) mediates this feedback mechanism (6, 7) . However, the manner in which trypsin regulates CCK release is unknown. We and others have postulated that a trypsin-sensitive CCK-releasing peptide (CCK-RP) is secreted into the lumen of the small bowel and releases CCK ( Fig. 1 ) (8, 9) . Rapid perfusion of the duodenum with saline prevented the rise of pancreatic secretion and CCK plasma levels stimulated by the diversion of bile-pancreatic juice. The administration of concentrated perfusate collected from a donor rat duodenum FIG. 1. A schematic representation of the postulated mechanism by which CCK-RP stimulates the secretion of CCK postprandially. CCK-RP is being secreted into the proximal small intestine and inactivated by trypsin. Postprandially, when food enters the duodenum, protein binds to trypsin and prevents CCK-RP from being inactivated. CCK-RP stimulates CCK cells in the duodenum to release CCK into the bloodstream.
CCK in turn stimulates pancreatic enzyme secretion.
into the duodenum of a recipient rat whose bile-pancreatic juice was diverted stimulated pancreatic secretion and CCK plasma levels. Treatment of the perfusate with trypsin, but not with amylase, lipase, or boiling, abolished the stimulatory effect of the perfusate. The secretion of this putative CCK-RP into the lumen appears to be under cholinergic control (8) and can be inhibited by somatostatin (10) . A similar mechanism has been postulated for the release of secretin (11) . Recently, Iwai et al. (12) isolated and sequenced a 61-aa trypsin-sensitive CCK-RP from pancreatic juice that was termed monitor peptide. The peptide is localized in the zymogen granules (13) and stimulates CCK release and pancreatic exocrine secretion. The physiological role of this peptide is unclear, however, because it cannot explain the pancreatic feedback mechanism stimulated by diversion of bile-pancreatic juice.
In this paper, we are reporting the isolation and characterization of a duodenal CCK-RP from pig intestinal mucosa that is secreted into the lumen and may regulate the negative feedback regulation of exocrine pancreatic secretion in rats.
MATERIALS AND The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. tetrodotoxin (TTX), DBI33-52, and alginic acid were purchased from Sigma; N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes) was purchased from Merck. The calcium ionophore A23187 was from Boehringer Mannheim; Sephadex G-50 was from Pharmacia; gastrin-releasing peptide (GRP) and antiserum of diazepam binding inhibitor33_50 were from Peninsula Laboratories. The CCK antagonist MK-329 was a gift of Merck Sharp & Dohme.
Preparation of the Intestinal Extract. A crude extract of pig intestinal mucosa was prepared using a modified method as described by Mutt (14) . In brief, the mucosa of the upper 30-40 cm of the small bowel distal to the papilla was scraped off and immediately frozen in liquid nitrogen. The mucosa was minced, boiled in 0.5 M acetic acid for 10 min after adding 1 mM DTT and 1 mM PMSF, and then rapidly chilled and homogenized. After centrifugation, peptides in the supernatant were adsorbed on alginic acid at pH 2.7, eluted with 0.2 M HCl, and precipitated by NaCl at saturation. The precipitate was dissolved in 33% ethanol and the pH adjusted to 7.2. After filtration, water was added to the filtrate and the peptides in the solution were readsorbed onto alginic acid and precipitated with NaCl, and the precipitate was dissolved in methanol. After a second filtration, the peptides in the filtrate were precipitated by the addition of ether. About 60 kg of intestinal mucosa yielded 70 g methanol soluble peptide fraction after lyophilization.
In Vivo Assay. Male, unfed, Sprague-Dawley rats weighing between 220 and 270 g were anesthetized with a mixture of xylazine and ketamine (13 and 87 mg/kg body weight i.m., respectively) and prepared with bile-pancreatic, intestinal, and jugular fistulas as described by Lu et al. (8) . Body temperature was maintained at 37°C with a heating pad. Atropine (150 ,tg/kg per hr dissolved in saline) was infused into the jugular vein from the beginning of the experiment after a bolus injection (75 ,ug/kg) to prevent the endogenous release of CCK-RP (8) . Bile-pancreatic juice was diverted and collected in small vials for 15-min periods, the volume determined, and amylase measured using an autoanalyzer (Eppendorf ACP 5040, Hamburg) according to the method of Kruse-Jarres et al. (15) . Bile-pancreatic juice protein was measured spectrophotometrically using the assay method of Bradford (16) . SBTI in 0.05 M sodium bicarbonate (pH 7.4) was infused intraduodenally at 1 mg per hr throughout the experiment. After establishing a stable baseline secretion (-2 hr after the start of the experiment) mucosal extracts or synthetic porcine diazepam binding inhibitor (DBI) dissolved in sodium bicarbonate (pH 7.4) were infused over a 15-min period. Samples that stimulated amylase output were further purified by HPLC. To evaluate whether the CCK antagonist MK-329 could block the stimulatory action of the mucosal extracts or synthetic porcine DBI, MK-329 (1 mg/kg) was given intravenously 30 min before the intraduodenal infusion. MK-329 was dissolved in 1:1 dimethyl sulfoxide (DMSO)/polysorbate 80 and diluted with saline to a final concentration of 1%.
To determine if DBI was released in the duodenum after diversion of bile-pancreatic juice, rats were prepared as described above and then perfused with 0.05 M sodium bicarbonate at a rate of 1 ml/min. The concentrated perfusate was assayed by radioimmunoassay using DBI33-52 antibody.
Structural Analysis. The amino acid composition of the purified peptide (0.7 ,ug) was analyzed with a Hitachi model L-8500 amino acid analyzer after hydrolysis of the sample in 6 M HCl containing 1% phenol at 110°C for 24 hr in an evacuated tube. The intact peptide (-6 ,g) was dissolved in 6 ,ul of 50 mM sodium bicarbonate (pH 8.3) containing trypsin at 0.2 ,ug and digested for 18 hr at room temperature. The peptide mixture obtained was separated by reverse-phase HPLC on a YMC-Pack ODS-5 column (4.6 x 250 mm) and eluted with a linear gradient of acetonitrile in 0.1% trifluoroacetic acid at a flow rate of 1 ml/min. The amino acid sequences of the peptide following trypsin digestion were determined with an Applied Biosystems model 477A gasphase protein sequencer equipped with an on-line phenylthiohydantoin amino acid analyzer. Molecular weights of the purified CCK-RP and the synthetic porcine DBI1I86 were measured using a matrix-assisted laser desorption ionization time of flight mass spectrometer (Kompact MALD III, Kratos Analytical Instruments). Peptide samples were mixed with 1% sinapinic acid in 50% ethanol and allowed to air dry before loading to the mass spectrometer.
Synthesis of DBI1l86. Porcine DBI was synthesized using an Applied Biosystems model 431A automatic peptide synthesizer on p-alkoxybenzyl alcohol resin with a Fmoc protection strategy and a coupling strategy using 2-(1H-benzotriazol-1-yl)-1,1,2,2-tetramethyluronium hexafluorophosphate. The side chains of serine, threonine, and tyrosine were protected with t-butyl group; arginine was protected with 4-methyoxyl-2,3,6-trimethylphenylsulfonyl (MTR) group; asparagine and glutamine were protected with trityl group; aspartic acid and glutamic acid were protected with O-butyl group; lysine and histidine were protected with t-Boc group. The peptide was deprotected and cleaved from the resin by treatment with trifluroacetic acid/thioanisole/ethandithiol/anisole (90:5:3:2)
for 6 hr at room temperature. After filtration and removal of the cleavage reagents and precipitation with anhydrous ether, the crude synthetic peptide was purified by HPLC.
In Vitro Assay. Dispersed intestinal mucosa cells were prepared as described by Bouras et al. (17) . Briefly, 20 cm of the proximal small bowel of male Sprague-Dawley rats, 2 cm distal to the pylorus was removed, washed with saline, and incubated for 10 min in 15 ml of oxygenated calcium-free KHB buffer containing 2.5 mM EDTA. After gentle shaking of the incubation flask, the remaining tissue was removed and the cell suspension was centrifuged. The pellet was rewashed twice with fresh Krebs-Henscleit bicarbonate (KHB) buffer with calcium and filtered through 200 ,um gauze (17) . The cell suspension (2 ml) was mixed with 2 ml of preswollen Sephadex G-50 medium resin and perfused in a perfusion apparatus at 1 ml/min (18) . After a 50-min period, perfusates collected for two 5-min periods were taken as basal level followed by three 5-min periods in which the stimulatory agent was added. The 15-min stimulation period was followed by four additional 5-min periods. CCK released into the medium was assayed as described (19) .
Statistics. Results are expressed as mean ± SEM. Data were analyzed using the Student's t test for unpaired data. Statistical significance was set at P < 0.05.
RESULTS
Extraction, Purification, and Sequencing of CCK-RP from Porcine Intestinal Mucosa. The peptides in the proximal small bowel mucosa were extracted, adsorbed on alginic acid, salt precipitated, and dissolved in methanol. This extraction protocol yielded -70 g of crude peptide material, which was further purified by HPLC (Fig. 2 a-d) . In each purification step, HPLC fractions were assayed for the stimulation of pancreatic enzyme secretion using anesthetized and atropinized rats prepared with jugular, bile-pancreatic, and intestinal fistulas. In the final HPLC purification step (Fig. 2d) , we obtained a pure peptide that was rich in Asx, Glx, and Lys by amino acid analysis ( Table 1 ). The intact peptide was subjected to amino acid sequence analysis, but we were unable to obtain any sequence data suggesting that the peptide had a blocked N terminus. After digestion of the peptide with trypsin and separation of the tryptic fragments by HPLC, we determined the sequences of eight fragments (Fig. 3) , which were identical to the corresponding fragments of porcine DBI originally isolated from rat brain (20 The peptide is rich in Asx, Glx, and Lys. the molecular mass of porcine intestinal DBIi-86 (Fig. 4) .
Structural analysis showed that we had indeed isolated porcine /X a DBIl-86 while in search of a CCK-RP from the proximal small bowel.
Luminal Secretion of DBI-Like Immunoreactivity During
Diversion of Bile-Pancreatic Juice. To examine whether DBIl-86 is secreted from the duodenal mucosa in the lumen, we used anesthetized rats prepared with bile-pancreatic and intestinal cannula as described above (8) . After diversion of bile-pancreatic juice, the duodenum was perfused with sodium bicarbonate-buffered saline (pH 7.4) at 1 ml/min and intestinal perfusates collected every 15 plasma CCK release (Fig. 6 ). DBIl-86 or its fragments had no effect on amylase secretion from isolated acini (data not shown).
In Vitro Action of DBI1l86 and DBI33-52 on CCK Secretion.
To further investigate the mechanism by which DBI stimulates CCK secretion, we used a perfusion system of dispersed intestinal mucosa cells as described by Bouras et al. (17) . In this perfusion system, we were able to show that KCl, calcium ionophore A 23187, and GRP stimulated CCK release (Fig.  7a) . DBIl-86 (10-9_10-13 M) dose-dependently stimulated CCK release with a maximum effect at 10-9 M (Fig. 7b) . Similarly, DBI33-52 stimulated CCK release but on a molar basis more than 100 times less potent than DBIl-86 (Fig. 7c) .
The CCK release was unaffected by the presence of neurotoxin tetrodotoxin, indicating that DBI directly stimulates CCK release without any neural involvement. DISCUSSION DBI is a peptide with wide tissue distribution and multiple biological functions (21) . It was first isolated from rat brain in 1983 (20) and subsequently found to be present in a number of peripheral organs. The highest concentration of DBI-like immunoreactivity and mRNA levels are found in the cerebral cortex, hypothalamus, liver, duodenum, testis, kidney, and adrenal cortex (21) . The first biological action described was its ability to displace diazepam from the GABA (y-aminobutyric acid)-A receptor (20) . This may be responsible for its wellknown properties of producing conflict behavior in rats when injected intracerebroventriculary. The action of DBI was blocked by the benzodiazepine antagonist flumazenil (22) . In addition, DBI has been reported to function as a high affinity acetyl coenzyme A binding protein (23) , as well as to act as an intracellular activator of mitochondrial steroid synthesis (24) . Stimulation of steroidgenesis is mediated through a peripheral-type benzodiazepine receptor, which is subcellularly located at mitochondrial membranes in most tissues (21) . Recently, cell surface receptors on the plasma membrane have been demonstrated on adrenal cortical cells and Leydig cells (25, 26) . (26) .
In the gastrointestinal tract, DBI immunoreactivity was detected in the secretory and absorptive epithelial cells of the gut with the highest DBI content in the antrum, duodenum, and colon (27) . Endocrine cells of the APUD system, Brunner glands, or neuronal cells in the myenteric plexus were devoid of DBI-immunoreactive material. In situ hybridization studies showed high density of DBI mRNA in the epithelial cells of the intestinal villi in the rat duodenum (27) . Chen et al. (28) isolated the 86 amino acid peptide DBI from porcine intestine.
They found that 10 nM DBII inhibited both early and late phases of glucose-induced insulin release from the isolated perfused rat pancreas. In addition, DBI (10-8_10-7 M) also significantly inhibited 3-isobutyl-1-methylxanthine (IBMX)-(1 ,uM) or glibenclamide (1 ,ug/ml)-stimulated insulin release in the presence of glucose (29) . Using an antibody against purified porcine DBI1l86, Johansson et al. (30) showed that DBI-like immunoreactivity was present in glucagoncontaining cells of rat pancreatic islets, suggesting a possible physiological role in modulating insulin secretion.
During our search for a CCK-RP in the duodenum responsible for the feedback regulation of pancreatic enzyme secretion, we isolated a peptide from the porcine intestinal mucosa that has a sequence identical to DBI. The peptide has a blocked N terminus, which helps to explain our initial difficulty to obtain sequence data. We showed that DBI is released into the intestinal lumen under cholinergic control and that it is capable of releasing CCK in vivo and in vitro. The ability of DBI to release CCK was not affected by the presence of luminal contents such as casein (unpublished data). Using an isolated mucosa cell system, we demonstrated that the synthetic porcine DBI1I86 stimulated CCK secretion at a concentration as low as 10-12 M. DBI33-52 also stimulated CCK release and pancreatic secretion although it is 100 times less potent than the whole peptide. DBI possesses several tryptic cleavage sites and tryptic digestion results in loss of its ability to stimulate CCK secretion. Therefore, we have isolated a trypsin-sensitive peptide that is secreted intraduodenally, releases CCK, and stimulates pancreatic secretion. This peptide fulfills all the criteria necessary to be the CCK-RP responsible for mediating feedback regulation of pancreatic secretion.
The mechanism(s) by which DBI releases CCK is unclear. Our in vitro studies demonstrate that the ability of DBI to release CCK was unaffected by tetrodotoxin, indicating that DBI directly stimulates CCK release without any neural involvement. It has been reported that basic peptides such as spermidine (a polyamine) may release CCK (31) . DBI contains 16 basic amino acids and 15 acidic amino acids. Because the N terminus of the peptide is blocked and the C terminus is not, this adds one more acidic group and makes porcine DBI a neutral protein. However, the absence of a net basic charge does not preclude a charge effect of DBI to release CCK. Further studies are needed to examine the cellular mechanism(s) by which DBI releases CCK.
Until now, regulatory peptides were believed to act in an endocrine or paracrine fashion to mediate a physiological process. Recently, gut peptides such as somatostatin (32) and peptide YY (33) have been shown to be released into the bowel lumen, but their physiological functions remain unknown. The pancreatic monitor peptide found exclusively in zymogen granules of pancreatic acinar cells is present in pancreatic juice (34) and can stimulate CCK release when it enters the duodenum (35) . This peptide has a partial sequence homology to the 14 residual sequence of epidermal growth factor and has been shown to stimulate growth in Swiss 3T3 cells (36) . The physiological function of this peptide is still unclear but because it is only present in the pancreatic juice it is clearly not involved in the feedback regulation of pancreatic secretion first reported by Green and Lyman (2) . In contrast, DBI, for all the reasons listed above, is likely to be the peptide responsible for mediating feedback regulation of CCK release by pancreatic proteases. This would be the first demonstration of a complete feedback loop in the gut for maintaining homeostasis during digestion. Our study also demonstrates an important physio-logical role for a luminal peptide and this may represent a new concept in the regulation of secretion of gut peptides.
